Qyuns Therapeutics Co., Ltd. Class H · HKEX:2509
Qyuns Therapeutics Co., Ltd. Class H — H1 2024 Earnings Presentation
31 slides from Qyuns Therapeutics Co., Ltd. Class H's earnings presentation, Aug 16, 2024
Slide 1: Interim Results 2024
INTERIM RESULTS 2024 16 Aug 2024 02509.HK 0
Slide 2: Disclaimer
Disclaimer NOT FOR PUBLICATION OR DISTRIBUTION, DIRECTLY OR INDIRECTLY, IN OR INTO THE UNITED STATES OR ANY OTHER JURISDICTION IN WHICH SUCH PUBLICATION OR DISTRIBUTION WOULD BE PROHIBITED BY APPLICABLE LAWS By attending this presentation or by reading this document, you (1) agree to be bound by the
Slide 3: Qyuns at a Glance
Qyuns at a Glance A clinical-stage biotech company exclusively focused on biologic therapies for autoimmune and allergic diseases Exclusive Focus Full Coverage Huge Market Comprehensive Pipeline Focus on autoimmune and allergic Cover four major disease areas in Global market size of US$187.5 9 drug
Slide 4: Exclusive focus on autoimmune and allergic disease therapies, covering four major disease areas
Exclusive focus on autoimmune and allergic disease therapies, covering four major disease areas and key therapeutic pathways Therapeutic Skin pipelines prioritized to build leading position in industry IL-12/IL-23p40 Psoriasis Ankylosing Spondylitis IL-23p19 Psoriasis IL-17A Lupus Nephritis Atopic D
Slide 5: Seasoned Management Team with Extensive Industry Experience and Successful Entrepreneurial Track Records
Seasoned Management Team with Extensive Industry Experience and Successful Entrepreneurial Track Records Jianwei Li, Ph.D. Jiwan Qiu Chief Operating Officer, Executive Director, Chairman, CEO, General Manager Deputy General Manager, General Manager of Cellularforce Min Fang 30 years of extensive R&D
Slide 6: Overview
01 Innovation & Focus: Seeking progress in stability 02 Qyuns: Strategic cooperation accelerating clinical advancement Overview 03 Cellularforce: Upgraded self-supporting business model 04 Financial Results 05 Future Outlook 5
Slide 7: Innovation & Focus: Seeking progress in stability
01 Innovation & Focus: Seeking progress in stability 6
Slide 8: Innovation & Focus: Seeking progress in stability
Innovation & Focus: Seeking progress in stability Pipeline Advancement • Key clinical trials on schedule • Differentiation & Innovation • Improve efficiency and focus on core pipeline Strategic Cooperation • Synergistic cooperations to advance clinical development • Cash inflow from cooperation paym
Slide 9: Qyuns H1 Performance Highlights
Innovation & Focus: Seeking progress in stability Qyuns H1 Performance Highlights Pipeline Advancement Strategic Cooperation Cash Inflow • QX005N： • QX008N： • IPO Jan: BTD for PN Jan: Cooperation with Joincare Listed on SEHK on 20 March 2024 Apr: Ph ll LPI for • BD Income May: Ph lll FPI for Adult A
Slide 10: Qyuns: Strategic cooperation accelerating clinical advancement
Qyuns: 02 Strategic cooperation accelerating clinical advancement 9
Slide 11: Comprehensive and Synergized Pipeline
Comprehensive and Synergized Pipeline 10
Slide 12: Product Matrix by Therapeutic Areas
Product Matrix by Therapeutic Areas The position of our pipeline assets in context Skin Rheumatic Respiratory Digestive Ps AD PN CSU Pruritus AS SLE LN CRSwNP Asthma COPD CD UC QX002N IL-17A QX005N IL-4Rα QX001S IL-12/IL-23p40 QX004N IL-23p19 QX006N IFNAR1 QX008N TSLP QX007N IL-33 QX013N c-kit QX010
Slide 13: QX005N – IND-Approved Indications
QX005N – 7 IND-Approved Indications QX005N Strategic Cooperation • IL-4Rα controls the signaling of both IL-4 and IL-13, which is critical in the initiation of type 2 inflammation • QX005N is designed to inhibit IL-4Rα, a well-validated, ⚫ In July 2024, the exclusive joint development rights, exclus
Slide 14: QX005N – 1st Biologic Drug Candidate for PN Developed by Chinese Domestic Company
QX005N – 1st Biologic Drug Candidate for PN Developed by Chinese Domestic Company Market Opportunities and Competition Unmet Medical Needs • Development of the PN drug market in China is still at an Prevalence of PN in China, 2017-2030E Limitation of Thousand current early stage treatment • Current
Slide 15: QX005N – IL-4Rα mAb for Moderate-to-Severe AD
QX005N – IL-4Rα mAb for Moderate-to-Severe AD Market Opportunities and Competition Clinical Development Market Opportunities IL-4Rα mAb Sales Soaring in China AD patients in China reached 70.3 million in Phase III > FPI in May 2024 2022 and is anticipated to reach 78.5 million CAGR=325.0% 248.1 in 2
Slide 16: QX002N – IL-17A mAb for AS
QX002N – IL-17A mAb for AS Market Opportunities and Competition Competitive Advantages Market Opportunities IL-17A vs. TNF The AS patient population in China reached 3.9 million in 2022, mainly younger ✓ Guided as 2L standalone treatment for AS, IL-17A inhibitors have shown adults clear clinical ben
Slide 17: QX001S – Ustekinumab Biosimilar for Moderate-to-Severe Plaque Ps
QX001S – Ustekinumab Biosimilar for Moderate-to-Severe Plaque Ps Market Opportunities and Competition Competitive Advantages Market Opportunities Ustekinumab Global Sales Expected to be the first marketed Ustekinumab Biosimilar in China The Ps patient population in China is ✓ The first and only Uste
Slide 18: QX004N – IL-23p19 mAb for Psoriasis and Crohn's Disease
QX004N – IL-23p19 mAb for Psoriasis and Crohn’s Disease IL-23p19 is currently a better target for psoriasis. Same target competitor The treatment effect of psoriasis will be further improved, The global sales of Skyrizi®, the same target competitor, were $1.59 and it is conducive to long-term manage
Slide 19: QX008N – TSLP mAb for Respiratory Diseases
QX008N – TSLP mAb for Respiratory Diseases •TSLP is a cytokine expressed by the airway epithelium and sits Same target competitor The global sales of Tezspire®, a competitor with the same target, at the top of multiple inflammatory cascades. were $170 million in 2022 and $570 million in 2023, with a
Slide 20: QX013N – First Biologic Drug Candidate Targeting c-kit in China
QX013N – First Biologic Drug Candidate Targeting c-kit in China QX013N is a humanized IgG1 monoclonal antibody independently developed by Qyuns and is the first biologic drug candidate targeting c-kit in China. We completed FPI in June 2024 for the indication of chronic spontaneous urticaria (CSU).
Slide 21: Strategic Collaborations – Further Strengthening Commercialization Certainty
Strategic Collaborations – Further Strengthening Commercialization Certainty QX008N 24 Jan 2024 We entered into a technology transfer agreement with Joincare to grant Joincare an exclusive license to develop, manufacture and commercialize QX008N in China, Hong Kong and Macau QX004N 24 Apr 2024 We en
Slide 22: Cellularforce: Upgraded self-supporting business model
Cellularforce: 03 Upgraded self-supporting business model 21
Slide 23: Commercial-Scale In-house Manufacturing Capacity Ensuring Stable and Cost-Controllable Supply
Commercial-Scale In-house Manufacturing Capacity Ensuring Stable and Cost- Controllable Supply of Products cGMP-standard manufacturing facility with excelled CMC capability One of only a few Chinese biotech companies that are focused on and quality management will secure high quality, cost controlla
Slide 24: Financial Results
0) =" © Financial Results
Slide 25: 1st Time Revenue Realization Further Strengthens Capital Reserve
1st Time Revenue Realization Further Strengthens Capital Reserve Mil RMB 50 44.92 In the first half of 2024, the total revenue of Qyuns was RMB 45 44.92 million, further strengthening the company's capital 40 reserves. It mainly came from the upfront payments and 35 clinical compensation fees from e
Slide 26: Rational Expense Management Improves Operational Efficiency
Rational Expense Management Improves Operational Efficiency R & D Expenses in the first HY of 2023 – 2024 Administrative Expenses in the first HY of 2023 – 2024 Mil RMB Mil RMB 180 168.84 120 160 145.23 98.77 100 140 120 80 70.33 100 60 80 60 40 40 20 20 0 0 2023.6.30 2024.6.30 2023.6.30 2024.6.30 I
Slide 27: Strengthened Capital Reserve and Liquidity Ratio
Strengthened Capital Reserve and Liquidity Ratio Mil RMB The cash and cash equivalents, restricted cash and financial assets recorded at fair 700.00 value increased from RMB376.71 million as of 31 December 2023 to RMB650.09 650.09 million as of 30 June 2024, and the relevant cash reserves increased
Slide 28: Licensing Revenue Significantly Improves Operating Cashflow
Licensing Revenue Significantly Improves Operating Cashflow Mil RMB Net cash outflow from operating activities 180 168.37 In the first half of 2024, net cash outflow from operating 160 activities of Qyuns was RMB66.85 million, a significant 140 decrease of 60.3% compared to RMB168.37 million in the
Slide 29: Future Outlook
0) =" ©& Future Outlook
Slide 30: Future Outlook
Future Outlook 1 Focus on core pipelines and continuously offer differentiated innovative therapies to benefit company value creation 2 Expand diversified business cooperation models to achieve win-win synergies 3 Cooperating with leading pharmaceutical companies to further improve product commercia
Slide 31: IR@qyuns.net
IR@qyuns.net 30